How the classic computer game Doom became a tool for science

Researchers at Cortical Labs trained neurons grown on a silicon chip to play the video game Doom, following an earlier 2021 demonstration of neurons playing Pong. The article highlights Doom’s 1997 published source code and small storage footprint as enabling cross-platform experiments and cites other novel demonstrations—such as MIT using E. coli as black-and-white pixels to display Doom frames—underscoring the use of video games as adaptable testbeds for AI, synthetic-biology interfaces and playful scientific exploration.

Analysis

The visible consequence for public markets is not a new product but a reallocation of optionality toward infrastructure: companies that sell reliable, recurring consumables, high-throughput electrode chips, and lab automation will capture the early spending that follows proof-of-concept media cycles. If just a handful of commercial projects move from demonstration to reproducible pipelines, expect incremental instrument/consumables revenue growth of 1–3% annually for market leaders over 12–36 months, materially higher margin and cash conversion than speculative R&D services.

Open-source cultural dynamics compress barriers to entry while fragmenting IP capture; that combination favors scale players that can bundle hardware + proprietary reagents and regulatory compliance. Cloud and data orchestration vendors will see secondary demand (medium: 12–24 months) for secure experiment telemetry and model training, but that is likely to be a small, concentrated revenue stream until standards and regs firm up.

Key risks are non-technical: reproducibility failures, regulatory/ethical interventions, and adverse media or biosecurity events could wipe sentiment rapidly. Catalysts to monitor over the next 6–24 months are (a) sustained commercial partnerships announced by tier-1 pharma or defense agencies, (b) repeatable multi-site protocols, and (c) modular product launches from instrument leaders; absence of these will reinstate a hype-to-drawdown cycle.

The most common misread will be to conflate viral publicity with durable TAM expansion. The market should pay up for infrastructure optionality, not one-off PR wins. That argues for overweighting diversified life-science platforms and employing option-like exposure to broader AI infrastructure rather than owning speculative wetware-native names outright.

Key Decisions for Investors

• Buy DHR (Danaher) — 12–24 month horizon. Target +12–18% total return if infrastructure demand materializes; place a hard stop at -8%. Rationale: durable consumables + instrument exposure to any scale-up in experimental activity.
• Buy TMO (Thermo Fisher) on pullbacks — 12–24 month horizon. Target +10–15% with downside protection via 6–12 month collars if available. Rationale: market share in high-margin reagents, automation, and regulatory services.
• Buy a modest NVDA 9–12 month call spread (debit call spread) as optionality on accelerated hybrid wet/dry AI workloads. Risk defined to premium paid; reward amplified if broader AI spend re-accelerates (~>20% upside in NVDA).
• Pair trade: Long DHR / Short IBB (equal dollar) — 6–12 months. Expected to outperform if capital rotates from speculative biotech into infrastructure. Trim or unwind if IBB materially outperforms biotech index or if a major reproducible commercialization announcement occurs.